Guideline for PET/CT imaging of neuroendocrine neoplasms with <sup>68</sup>Ga-DOTA-conjugated somatostatin receptor targeting peptides and <sup>18</sup>F-DOPA.

View/ Open
Publication Date
2017-08Author
Bozkurt, MF
Virgolini, I
Balogova, S
Beheshti, M
Rubello, D
Decristoforo, C
Ambrosini, V
Kjaer, A
Delgado-Bolton, R
Kunikowska, J
Oyen, WJG
Chiti, A
Giammarile, F
Sundin, A
Fanti, S
Type
Journal Article
Metadata
Show full item recordAbstract
<h4>Purpose & methods</h4>Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using <sup>68</sup>Ga-DOTA-conjugated peptides, as well as <sup>18</sup>F-DOPA imaging for various neuroendocrine neoplasms.<h4>Results & conclusion</h4>The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with <sup>68</sup>Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
Collections
Version of record
Subject
Humans
Neuroendocrine Tumors
Gallium Radioisotopes
Dihydroxyphenylalanine
Heterocyclic Compounds, 1-Ring
Peptides
Receptors, Somatostatin
Image Interpretation, Computer-Assisted
Tissue Distribution
Quality Control
Practice Guidelines as Topic
Positron Emission Tomography Computed Tomography
Research team
Translational Molecular Imaging
Language
eng
Date accepted
2017-05-09
License start date
2017-08
Citation
European journal of nuclear medicine and molecular imaging, 2017, 44 (9), pp. 1588 - 1601